Insmed Inc.
Insmed Inc. is a biopharma leader targeting serious and rare diseases, with a growing pipeline that includes phase‑3 ARIKAYCE for NTM lung infection, Brensocatib for bronchiectasis, treprostinil palmitil for pulmonary hypertension, and early‑stage gene‑therapy candidates.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 1,271
- HQ: Bridgewater
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.